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treating such patients. Sixty-three autologous HSCT were per-
formed from August, 1994 to September, 2003; 80% of them were
after 1999. Thirty-four patients were male (54%). The median age
was 7 years (1 to 23). The underlying diagnoses were neuroblas-
toma (24), Wilms’ tumor (10), Ewing’s Sarcoma (9), medulloblas-
toma/ central nervous system primitive neuroectodermal tumor
(8), germ cell tumors (6), rhabdomyosarcoma (5) and desmoplasic
small round cell tumor (1). Twenty-one patients with neuroblas-
toma, two with medulloblastoma (under 3 years of age) and one
with metastatic rhabdomyosarcoma were in ﬁrst remission. The
others were in second or third remission or had refractory disease
(39). Melphalan, etoposide and carboplatin was the conditioning
regimen used in 68% of the patients. The peripheral blood was the
source of stem cells in 72% of them. The overall and disease free
survival at four years were 39  8% and 33  7%, respectively.
The median survival was 22  6 months. The overall survival,
according to diagnosis, was 53  11% for neuroblastoma, 58 
16% for Wilms’ tumor, 33 16% for Ewing’s sarcoma, 58 19%
for medulloblastoma, 50  29% for germ cell tumors and 20 
18% for rhabdomyosarcoma. Relapse was the main cause of
death (21/63-32%). Nine patients (14%) died due to trans-
plant-related toxicity or infections. In conclusion, HSCT is
feasible but carries a high transplant-related mortality. A Brazilian
HSCT registry is being organized. National trials are warranted
for better indication and evaluation of the role of stem cell trans-
plantation in the treatment of high-risk or relapsed pediatric solid
tumors.
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AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) IN PEDIATRIC
PATIENTS WITH ADVANCED HODGKIN’S LYMPHOMA (HL): THE ROLE
OF INTERFERON-ALPHA POST-TRANSPLANT
Petropoulos, D.1, Worth, L.L.1, Mullen, C.A.1, Lockhart, S.2, Ramirez,
I.1, Chan, K.W.1 1. MD Anderson Cancer Center, Houston, TX; 2.
Children’s Hospital of Austin, Austin, TX
Interferon alpha (IFN	) has known anti-proliferative and immu-
nomodulating effects and might enhance immunity for better con-
trol of any residual HL after SCT. Between May 1994 and August
2003 a total of 12 pediatric (8 males) patients with HL (8 NS, 2 LP,
1MC, 1 NSALCL) underwent autologous SCT in our center.
Their median age was 16 (range 11-20) years. The median interval
between diagnosis and transplant was 16 months (range 6mos-9 y).
All patients had received a median of 3 prior treatments (range 2-4)
and all but two additional involved-ﬁeld radiotherapy. Disease
status at the time of SCT was: PD (4 patients), SD (2), PR (4), and
CR(2). The conditioning regimens were BEAM (n 6), CBV (n
3), or other(n  3) The source of SC was autoBM in 2 cases and
autoPBSC in 10. All patients achieved ANC and PLT engraftment
after a median time of 10 (9-16) and 12 (11-31) days respectively.
Nine patients received IFNa immunotherapy when the ANC and
the platelet count exceeded 1,500 and 50,000 respectively. Three
did not, two due to rapidly progressive disease. Interferon-	 ad-
ministration was initiated at a dose of 0.5 million Units/m2 tiw
(Klingerman et al, Blood 1991,78: 3306) at a median of 49 days
post-transplant (range 33-127). Patients received IFN	 for 1 to 24
months (median 12 months post-transplant). Observed toxicity was
hematologic and constitutional, with escalation of dose and/or
frequency as permitted by toxicity. The median tolerated weekly
dose was 3.5(range 1.5-6.5) mU/m2. With a median follow-up of
41(range 2-113) months, nine patients are alive and well (two less
than a year post SCT). Of the 10 patients who received IFN	, nine
are alive with no evidence of disease. Three patients died: two from
rapidly progressive HL (did not receive IFN	) and one from
relapse following allogeneic BMT. One patient, who relapsed after
transplant, was treated with IFN	 and chemotherapy and remains
in remission 5 years later. In conclusion, IFN-	 administration to
pediatric patients following SCT for advanced HL is safe and may
confer survival advantage.
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STEM CELL TRANSPLANTATION (SCT) FOR PATIENTS(PTS) WITH GE-
NETIC DISEASES: A CALL FOR PHYSICIANS FROM DEVELOPING COUN-
TRIES TO DISCUSS ABOUT STRATEGIES TO IMPROVE DIAGNOSIS AND
EARLY REFERRAL TO BMT CENTERS
Bonﬁm, C.M.S., Bitencourt, M.A., Setubal, D.C., Moreira, V.A.,
Lorenzato, C., Ruiz, J., Zanis Neto, J., de Medeiros, C.R., Pasquini, R.
BMT Center-Federal University of Parana, Curitiba, PR, Brazil
Background: Brazil is a huge Latin-American country with
many social and economic disparities and more than 3 million live
births every year. SCT for pts with genetic diseases (GD) has a
speciﬁc timing because engraftment of donor cells does not always
correlate with improved quality of life or survival. Material and
Methods: Between 10/79 and 09/03 more than 1400 SCT were
performed in our BMT Unit but only 51 pts had GD. Median age:
3yr (range: 0,1 to 22). Gender: F11/M40; Diagnoses: Dyskeratosis
Congenita (DC): 5pts;Diamond-Blackfan Anemia (DBA): 5pts;
Congenital Dyserythropoietic Anemia (DBA): 1pt; Amegakaryo-
cytic Purpura (AmegaP): 1pt; Hemoglobinopathies: 4pts; Kost-
mann Syndrome: 1pt; Wiskott-Aldrich syndrome (WAS): 7pts;
Severe Combined Immunodeﬁciency (SCID): 7pts; Histiocytoses:
1pt; Gaucher disease: 1pt; Mucopolysaccharidosis: 6pts (MPS-I:
3pts, MPS-III: 1pt, MPS-VI: 2pts); Adrenoleukodystrophy (CO-
CALD): 3pts; Globoid Cell Leukodystrophy (GLD-Krabbe): 1pt;
Osteopetrosis (OP): 8pts. Bone marrow (BM) was the stem cell
source for 30 HLA-identical siblings, 3 other related and 1 hap-
loidentical (mother). 17pts received an unrelated transplant (11CB,
6BM). Conditioning regimen: Chemotherapy only: 41pts, Chemo-
therapy TBI: 7pts. No conditioning regimen: 3pts. GVHD pro-
phylaxis: Csa was given to 47pts. Results: 48pts were evaluable for
engraftment and 10pts had primary graft failure (osteopetrosis:
6pts). Thirty-three pts (DBA: 3pts; Gaucher: 1pt; MPS: 3pts; OP:
2pts, DC: 5pts, Hemoglobinopathies: 4pts, SCID: 6pts, WAS:
5pts; COCALD: 2pts; AmegaP: 1pt Histiocytoses: 1pt) are alive 6
to 5688 days post-BMT (Median: 1377days). Four pts are alive
with an autologous recovery (OP: 2pts, Hemoglobinopathies:
2pts). All pts with storage disease that are alive improved or
stabilized their neurological function, except for 1pt with MPS-III.
Eighteen pts died (14pts before day100). GVHD or graft-failure
associated with infections was responsible for most deaths. Con-
clusion: Medical education to improve early diagnosis and referral
to specialized centers is the key to success in GD. This has to be
done together with the commitment from the health system in
each country to guarantee that all pts will be able to receive
adequate treatment despite their economic or social background. It
is urgent that developing countries work together with interna-
tional centers to improve diagnosis, data collection and speciﬁc
treatments in these rare diseases.
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UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR FA-
MILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS
Archambault, B.L., Driscoll, T.A., Stafford, L.A., Szabolcs, P., Kurtzberg,
J., Martin, P.L. Duke University Medical Center, Durham, NC
Background: Patients with Familial Erythrophagocytic Lym-
phohistiocytosis (FEL) or Hemophagocytic Lymphohistiocytosis
(HLH) die of progressive disease early in life. Allogeneic stem cell
transplantation may be curative. However, many children lack a
suitably matched living related or unrelated donor. This study
investigated the feasibility of substituting partially HLA-mis-
matched, banked unrelated-donor umbilical cord blood (UCB) as
an alternative source of hematopoietic stem cells for transplanta-
tion in children with FEL lacking traditional HLA matched stem
cell donors. Methods: Five infants with FEL, with a median age of
0.58 years, (range 0.33-0.98) received myeloablative doses of busul-
fan, cyclophosphamide and ATG followed by unrelated UCB
transplantation between 11/98 and 2/02. Patients were evaluated
for donor cell engraftment, toxicity and effects of this therapy on
the natural history of the disease. Patients did not receive any post
transplant intrathecal therapy. No radiation therapy was adminis-
tered at any time during therapy. Results: UCB donors mis-
matched at 1-2 HLA markers delivering a median cell dose of
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11.19 107 cells/kg and 4.78 105 CD34 cells/kg were identiﬁed.
These cell doses were typically higher than typically seen with
UCB grafts because the patients were small (median weight 9.31kg,
range 4.75-11.63). All patients successfully engrafted with donor
cells and maintained complete donor chimerism post transplant.
The median time to engraftment (ANC  500/uL) was 17 days
(range 14-21). Engraftment of platelets (untransfused count of
50K/uL) occurred in 4/5 patients in a median of 72 days (range
31-94). One patient developed acute GvHD (grade 3) and none of
the surviving patients (n  4) developed chronic graft versus host
disease. One patient died of progressive liver failure related to
GvHD and severe hepato-toxicity 32 days after transplantation.
The remaining patients are surviving event-free for a median
follow-up of 4.4 years (range 3.3-4.9 years). Conclusions: Banked,
unrelated donor UCB is a readily available source of allogeneic
stem cells for transplantation of patients with FEL. Patients expe-
rience durable engraftment and low probabilities of severe acute
and chronic GvHD. Thus far, no patients have recurred. UCB
transplantation should be considered for all patients with FEL/
HLH who do not have a matched related donor.
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LATE CEREBRAL GRAFT VERSUS HOST REACTION IN A GIRL BONE
MARROW TRANSPLANTED BECAUSE OF HURLER (MPS I) DISEASE
Kyllerman, M.1, Himmelman, K.1, Fasth, A.2, Nordborg, N.3, Månsson,
M.4 1. Dept of Neurology, The Queen Silvia Children’s Hospital, Go¨teborg,
Sweden; 2. Dept of Oncology/Immunology, The Queen Silvia Children’s
Hospital, Go¨teborg, Sweden; 3. Dept of Pathology, Sahlgrenska University
Hospital, Go¨teborg, Sweden; 4. Dept of Clinical Neuroscience, Section of
Experimental Neuroscience, Go¨teborg University, Go¨teborg, Sweden
A today 7-year-old girl with Hurler disease (MPS I) underwent
bone marrow transplantation at 13 months of age with her one
HLA-B antigen mismatched mother as donor. The procedure was
complicated by intracranial hypertension, cerebral hemorrhage and
shunt operation for hydrocephalus. Symptoms of mild skin graft-
versus-host disease (GVHD) developed one year after transplantation
and were reversed by prednisolon and cyclosporin. Increased CSF
albumin and pleocytosis normalized concomitantly. Ventricular CSF
and CNS debris were analyzed by electron microscopy and showed
complex aggregates of thin lamellae and electron dense fragments
with a tight lamellar texture. Biochemical analysis proved the debris to
contain galactosylceramide and sulfatide. The ﬁndings were inter-
preted to represent stripping and desquamation of central myelin
sheaths as a result of subacute GVHD reaction in the central nervous
system. Her mental development at time of transplantation was in the
low normal range to mild mental retardation, while now at 7 years of
age she is in the upper range of severe mental retardation. After
reversal of the GVHD at 21⁄2 years of age until follow-up at 7 years of
age the clinical condition remained stable with no further deteriora-
tion. Peters C et al (Blood 1998;91:2601-8) found that GVHD II
has a signiﬁcant detrimental effect on neuropsychological outcome.
CNS GVHD was never part of the GVHD score, but the result of
Peters et al could be interpreted as indirect evidence of the presence
of CNSGVHD.Our ﬁndings, where we had the opportunity to study
ventricular ﬂuid cytology and biochemistry, are further evidence for
the presence of CNSGVHD. In this case, however, also other factors
beside GVHD might add to the poor neuropsychological outcome
such cerebral bleeding and ventricular shunt complications.
SOLID TUMORS
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INDIUM-111 LABELLED DONOR LYMPHOCYTE INFUSION VIA HEPATIC
ARTERY OR I.V. AGAINST LIVER METASTASES OF RENAL AND COLON
CARCINOMA AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL
TRANSPLANTATION
Barkholt, L.1,2, Danielsson, R.3, Calissendorff, B.3, Svensson, L.4, Ma-
lihi, R.5, Uzunel, M.2, Remberger, M.2, Ringden, O.1,2 1. Centre for
Allogeneic Stem Cell Transplantation; 2. Div. of Laboratory Medicine;
3. Dept. of Radiology; 4. Dept. of Medical Physics; 5. Pharmacy, Hud-
dinge University Hospital, Karolinska Institutet, Stockholm, Sweden
Objective: Antitumor effect occurs after allogeneic SCT in pa-
tients with metastatic solid cancer. However, this treatment is not
as effective against liver as pulmonary and lymph node metastases.
To intensify the effect of donor lymphocyte infusion (DLI) against
liver metastases, we hereby describe intra-arterial (i.a.) cell injec-
tion via the hepatic artery (HA). Methods: To trace the infused
cells, 3 patients with colorectal, 3 with renal and 1 with breast
carcinoma, in a series of 18 SCT patients, were treated with
Indium-111 (In-111) oxinate labelled lymphocytes. Four patients
received the DLI via HA. They were compared with 2 patients
with other metastasis and a patient without CT proven ones using
In-111 DLI I.V. Results: Localisation of the i.a. In-111 DLI
activity on scintigrams corresponded to sites of liver metastases on
CT. In contrast, a homogenous isotope uptake over the lungs,
spleen and vertebrae was found after DLI I.V. After i.a. injection,
the liver to sternum ratio of radioactivity was initially high, but
resembled during the following days that of the other patients with
I.V. injection. Cells (CD3, 19, and 56) in biopsies of liver
metastases in 2 patients treated with i.a. injection were 80-100% of
donor origin. Two of 4 patients treated using the i.a. DLI showed
regression or stable size and number of liver metastases for 5 and
24 months, respectively. Both are alive 22 and 36 months after
SCT. Two of 3 patients receiving DLI I.V. are doing well with a
stable metastatic disease or still without liver metastases for 19 and
24 months after cell infusions (24 and 36 months after SCT),
respectively. Conclusion: When infused via HA, In-111 labelled
lymphocytes home to the liver metastases. The majority of liver
metastasis inﬁltrating cells was of donor origin, which supports our
aim to provide the DLI focally to liver metastases.
STEM CELL BIOLOGY
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OPTIMIZATION OF EX-VIVO EXPANSION CONDITIONS WITH DIFFER-
ENT GROWTH FACTOR COMBINATIONS AND CONCENTRATIONS MAIN-
TAINING LONG-TERM ENGRAFTING ABILITY OF UMBILICAL CORD
BLOOD CD34 STEM CELLS
Zhang, J.1, Brown, R.2, Heye, M.1, Welhausen, S.1, Nett, A.1, Burke,
C.1, Herzig, R.H.1 1. James Graham Brown Cancer Center, University
of Louisville, Louisville, KY; 2. Quality Biological, Inc., Gaithersburg,
MD
Expanding umbilical cord blood (UCB) stem cell numbers ex
vivo for transplantation in adults applications remains a challenge.
An improved understanding of how to optimize the cytokines for
expansion is needed. The aim of this study was to compare differ-
ent concentrations of cytokines in combination to deﬁne a cytokine
combination able to expand the umbilical stem/progenitor cells,
especially the immature CD34CD38-DR-cell subset, putatively
responsible for long-term engraftment in vivo. Isolated CD34
cells from UCB were cultured in a deﬁned serum-free medium
(QBSF-60) with stem cell factor, Flt-3 ligand, thrombopoietin,
IL-3, IL-6 IL-11, G-CSF, and erythropoietin. Two different con-
centrations of cytokines were used; group 1 with a higher concen-
tration, representing a 10-fold (one log) increase over the other,
group 2. Fresh media with cytokines was supplemented or ex-
changed at day 4, 7, and 10. The clonogenic efﬁciency, CD34
sub-populations and the expansion potential were determined on
day 7 and day 14 by evaluating the following parameters: clono-
genic progenitors(CFU-GM, BFU-E, CFU-GEMM and HPP-
CFC) and immunophenotypes(CD34 cells and CD34 sub-pop-
ulations) The expansion was done over a 14 day culture period.
The day 7 fold expansion was similar for both groups 1 and 2 (data
not shown). By day 14, group 1 yielded more nucleated cells (with
IL-3) of 971  75 fold expansion compared with 305  55 fold
expansion in group 2 and CD34 cells (with IL-3 and IL-6) of
33 4.5 and 26 4.9 fold-expansion compared with 6.8 2.2 and
16  5.9 fold-expansion in group 2. Further, group 1 culture
containing IL-6 yielded more CD34CD38-DR-cells of 31  12
fold-expansion compared with 11  2.1 fold-expansion in group 2.
The higher concentration group also produced more CFU-C and
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